Skip to main content
Erschienen in: Journal of Neural Transmission 5/2020

21.04.2020 | Neurology and Preclinical Neurological Studies - Review Article

The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson’s disease

verfasst von: Jeswinder Sian-Hulsmann, Peter Riederer

Erschienen in: Journal of Neural Transmission | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Misfolding of the protein α-synuclein contributes to the formation of the intracellular inclusion, Lewy bodies. Although these structures are not exclusive to Parkinson’s disease, nevertheless, their presence in the substantia nigra is mandatory for the pathological diagnosis of the disorder. Therefore, there must be a focus on the pathological mechanisms responsible for Lewy body generation. Recent studies have suggested that α-synuclein has the potential to operate as the enzyme ferrireductase. Perhaps in the early diseased state, overexpression or mutation of alpha-synuclein/ferrireductase invokes the dyshomeostasis of iron (III)/(II) only, while in advanced stages, accumulation of iron in particular areas of the brain follows. Furthermore, the loss of an important iron chelator, neuromelanin (due to dopaminergic neuronal death), may then result in the release and increase in unbound free iron. Iron could generate reactive oxygen species, which could instigate a torrent of cellular deleterious processes. In addition, loss of energy supply may contribute to the alteration in activity of enzymes involved in the mitochondrial respiratory chain and would, therefore, confer a vulnerability to the dopaminergic neurons in the substantia nigra. Therefore, the ferrireductase alpha-synuclein may hold the key for major pathology of Parkinson’s disease. In conclusion, we hypothesize that environmentally or genetically overexpressed and/or mutated α-synuclein/ferrireductase causes iron dyshomeostasis without increase of free iron concentration in the early phases of PD, while increased iron concentration accompanied by iron dyshomeostasis is a marker for progressed PD stages. It is essential to elucidate these degenerative mechanisms, so as to provide effective therapeutic treatment to halt or delay the progression of the illness already in the early phase of PD. The development of iron chelators seems to be a reasonable approach.
Literatur
Zurück zum Zitat Ben-Shachar D, Eshel G, Riederer P, Youdim MBH (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson’s disease. Ann Neurol 32:S105–S110PubMed Ben-Shachar D, Eshel G, Riederer P, Youdim MBH (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson’s disease. Ann Neurol 32:S105–S110PubMed
Zurück zum Zitat Brown DR (2013) α-Synuclein as a ferrireductase. Biochem Soc Trans 41(6):1513–1517PubMed Brown DR (2013) α-Synuclein as a ferrireductase. Biochem Soc Trans 41(6):1513–1517PubMed
Zurück zum Zitat Deas E, Cremades N, Angelova PR, Marthe HR, Ludtmann HR, Zhi Y, Chen S, Horrocks MH, Banushi B, Little D, Devine MJ, Gissen P, Klenerman D, Dobson CM, Wood NW, Gandhi S, Abramov AY (2017) Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease. Prog Neurobiol 155:96–119 Deas E, Cremades N, Angelova PR, Marthe HR, Ludtmann HR, Zhi Y, Chen S, Horrocks MH, Banushi B, Little D, Devine MJ, Gissen P, Klenerman D, Dobson CM, Wood NW, Gandhi S, Abramov AY (2017) Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease. Prog Neurobiol 155:96–119
Zurück zum Zitat Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R (2014) Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 21(2):195–210PubMedPubMedCentral Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R (2014) Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 21(2):195–210PubMedPubMedCentral
Zurück zum Zitat Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC, FAIRPARK-II, and FAIRALS-II studygroups (2020) Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm (Vienna). 127(2):189–203. https://doi.org/10.1007/s00702-019-02138-1(Epub 2020 Jan 7. Review) PubMed Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC, FAIRPARK-II, and FAIRALS-II studygroups (2020) Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm (Vienna). 127(2):189–203. https://​doi.​org/​10.​1007/​s00702-019-02138-1(Epub 2020 Jan 7. Review) PubMed
Zurück zum Zitat Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52(6):1830–1836PubMed Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52(6):1830–1836PubMed
Zurück zum Zitat Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FY, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Brain 114(4):1953–1975PubMed Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FY, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Brain 114(4):1953–1975PubMed
Zurück zum Zitat Double K, Zecca L, Costo P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 75:2583–2589PubMed Double K, Zecca L, Costo P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M (2000) Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 75:2583–2589PubMed
Zurück zum Zitat Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D (2003) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66(3):489–494PubMed Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MB, Riederer P, Ben-Shachar D (2003) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66(3):489–494PubMed
Zurück zum Zitat Flagmeier P, Meisl G, Vendruscolo M, Knowles TP, Dobson CM, Buell AK, Céline AG (2016) Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of α-synuclein aggregation. Proc Natl Acad Sci USA 113(37):10328–10333PubMedPubMedCentral Flagmeier P, Meisl G, Vendruscolo M, Knowles TP, Dobson CM, Buell AK, Céline AG (2016) Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of α-synuclein aggregation. Proc Natl Acad Sci USA 113(37):10328–10333PubMedPubMedCentral
Zurück zum Zitat Götz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M (2000) Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm (Vienna) 107(1):41–48 Götz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, Riederer P, Gerlach M (2000) Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm (Vienna) 107(1):41–48
Zurück zum Zitat Grünewald A, Rygiel KA, Hepplewhite PD, Morris CM, Picard M, Turnbull DM (2016) Mitochondrial DNA depletion in respiratory chain-deficient Parkinson disease neurons. Annals Neurol 79(3):366–378 Grünewald A, Rygiel KA, Hepplewhite PD, Morris CM, Picard M, Turnbull DM (2016) Mitochondrial DNA depletion in respiratory chain-deficient Parkinson disease neurons. Annals Neurol 79(3):366–378
Zurück zum Zitat Hamed MY, Silver J (1983) Studies on the reactions of ferric iron with glutathione and some related thiols. Part II. Complex formation in the pH range three to seven. Inorg Chim Acta 80:115–122 Hamed MY, Silver J (1983) Studies on the reactions of ferric iron with glutathione and some related thiols. Part II. Complex formation in the pH range three to seven. Inorg Chim Acta 80:115–122
Zurück zum Zitat Hamed MY, Silver J, Wilson MT (1983) Studies on the reactions of ferric iron with glutathione and some related thiols. Part III. A study of the iron catalyzed oxidation of glutathione by molecular oxygen. Inorg Chim Acta 80:237–244 Hamed MY, Silver J, Wilson MT (1983) Studies on the reactions of ferric iron with glutathione and some related thiols. Part III. A study of the iron catalyzed oxidation of glutathione by molecular oxygen. Inorg Chim Acta 80:237–244
Zurück zum Zitat Hebron ML, Lonskaya I, Moussa CE (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet 22(16):3315–3328PubMedPubMedCentral Hebron ML, Lonskaya I, Moussa CE (2013) Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet 22(16):3315–3328PubMedPubMedCentral
Zurück zum Zitat Joppe K, Roser A-E, Maass F, Lingor P (2019) The contribution of iron to protein aggregation disorders in the central nervous system. Front Neurosci 13:15PubMedPubMedCentral Joppe K, Roser A-E, Maass F, Lingor P (2019) The contribution of iron to protein aggregation disorders in the central nervous system. Front Neurosci 13:15PubMedPubMedCentral
Zurück zum Zitat Khan TR, Langford CH (1976) Kinetic and spectsophotometric studies of binding of iron(II1) by glutathione. Can J Chem 54:3192 Khan TR, Langford CH (1976) Kinetic and spectsophotometric studies of binding of iron(II1) by glutathione. Can J Chem 54:3192
Zurück zum Zitat Langley J, He N, Huddleston DE, Chen S, Yan F, Crosson B, Factor S, Hu X (2019) Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts. Mov Disord 34(3):416–419PubMed Langley J, He N, Huddleston DE, Chen S, Yan F, Crosson B, Factor S, Hu X (2019) Reproducible detection of nigral iron deposition in 2 Parkinson's disease cohorts. Mov Disord 34(3):416–419PubMed
Zurück zum Zitat Liu JL, Fan YG, Yang ZS, Wang ZY, Guo C (2018) Iron and Alzheimer's disease: from pathogenesis to therapeutic implications. Front Neurosci 12:632PubMedPubMedCentral Liu JL, Fan YG, Yang ZS, Wang ZY, Guo C (2018) Iron and Alzheimer's disease: from pathogenesis to therapeutic implications. Front Neurosci 12:632PubMedPubMedCentral
Zurück zum Zitat Martin LJ (2006) Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65(12):1103–1110PubMed Martin LJ (2006) Mitochondriopathy in Parkinson disease and amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 65(12):1103–1110PubMed
Zurück zum Zitat Martin-Ruiz C, Williams-Gray CH, Yarnall AJ, Boucher JJ, Lawson RA, Wijeyekoon RS, Barker RA, Kolenda C, Parker C, Burn DJ, Von Zglinicki T, Saretzki G (2020) Senescence and inflammatory markers for predicting clinical progression in Parkinson’s disease: the ICICLE-PD study. J Parkinson's Dis 10(1):193 Martin-Ruiz C, Williams-Gray CH, Yarnall AJ, Boucher JJ, Lawson RA, Wijeyekoon RS, Barker RA, Kolenda C, Parker C, Burn DJ, Von Zglinicki T, Saretzki G (2020) Senescence and inflammatory markers for predicting clinical progression in Parkinson’s disease: the ICICLE-PD study. J Parkinson's Dis 10(1):193
Zurück zum Zitat Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163(3):1450–1455PubMed Mizuno Y, Ohta S, Tanaka M, Takamiya S, Suzuki K, Sato T, Oya H, Ozawa T, Kagawa Y (1989) Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163(3):1450–1455PubMed
Zurück zum Zitat Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T (1988) Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. J Neural Transm 72(1):77–82PubMed Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T (1988) Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. J Neural Transm 72(1):77–82PubMed
Zurück zum Zitat Moors TE, Hoozemans JJ, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin MC, van de Berg WD (2017) Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol Neurodegener 12(1):11PubMedPubMedCentral Moors TE, Hoozemans JJ, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin MC, van de Berg WD (2017) Therapeutic potential of autophagy-enhancing agents in Parkinson's disease. Mol Neurodegener 12(1):11PubMedPubMedCentral
Zurück zum Zitat Müller T, Kohlhepp W (2018) Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson's disease. Med Hypotheses 110:46–49PubMed Müller T, Kohlhepp W (2018) Nigral depigmentation reflects monoamine exhaustion as initial step to Parkinson's disease. Med Hypotheses 110:46–49PubMed
Zurück zum Zitat Müller T, Trommer I, Muhlack S, Mueller BK (2016) Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease. J Neural Transm 123:401–406PubMed Müller T, Trommer I, Muhlack S, Mueller BK (2016) Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease. J Neural Transm 123:401–406PubMed
Zurück zum Zitat Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem 50(1):202–208PubMed Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K (1988) Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem 50(1):202–208PubMed
Zurück zum Zitat Reichmann H, Riederer P (1989) Biochemische Analyse der Atmungskettenkomplexe verschiedener Hirnregionen von Patienten mit Morbus Parkinson. In: Symposium des BMFT Morbus Parkinson und andere Basalganglienerkrankun-gen, S. 44 (abstr.) Reichmann H, Riederer P (1989) Biochemische Analyse der Atmungskettenkomplexe verschiedener Hirnregionen von Patienten mit Morbus Parkinson. In: Symposium des BMFT Morbus Parkinson und andere Basalganglienerkrankun-gen, S. 44 (abstr.)
Zurück zum Zitat Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52(2):515–520PubMed Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52(2):515–520PubMed
Zurück zum Zitat Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM (2019) α-Synuclein in Parkinson's disease: causal or bystander? J Neural Transm (Vienna) 126(7):815–840 Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Krüger R, Müller T, Reichmann H, Rieß O, Storch A, Strobel S, van Eimeren T, Völker HU, Winkler J, Winklhofer KF, Wüllner U, Zunke F, Monoranu CM (2019) α-Synuclein in Parkinson's disease: causal or bystander? J Neural Transm (Vienna) 126(7):815–840
Zurück zum Zitat Sian J, Dexter DT, Jenner P, Marsden CD (1991) Decrease in nigral reduced glutathione in Parkinson’s disease. Br J Pharmacol 104:281P Sian J, Dexter DT, Jenner P, Marsden CD (1991) Decrease in nigral reduced glutathione in Parkinson’s disease. Br J Pharmacol 104:281P
Zurück zum Zitat Sian J, Dexter D, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marden CD (1994) Alterations in glutathione in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Ann Neurol 36(3):348–355PubMed Sian J, Dexter D, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marden CD (1994) Alterations in glutathione in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Ann Neurol 36(3):348–355PubMed
Zurück zum Zitat Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 118(6):939–957PubMed Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 118(6):939–957PubMed
Zurück zum Zitat Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Trans 74:199–205 Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Trans 74:199–205
Zurück zum Zitat Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142(2):128–130PubMed Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142(2):128–130PubMed
Zurück zum Zitat Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171(2):273–285. https://doi.org/10.1016/j.cell.2017.09.021 PubMedPubMedCentral Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 171(2):273–285. https://​doi.​org/​10.​1016/​j.​cell.​2017.​09.​021 PubMedPubMedCentral
Zurück zum Zitat Talan J (2019) 3 Different clinical subtypes of Parkinson's disease. J Parkinsons Dis 5(4):699–713 Talan J (2019) 3 Different clinical subtypes of Parkinson's disease. J Parkinsons Dis 5(4):699–713
Zurück zum Zitat Ward RJ, Crichton RR. (2019) Ironing out the Brain. Met Ions Life Sci. Jan 14;1 Ward RJ, Crichton RR. (2019) Ironing out the Brain. Met Ions Life Sci. Jan 14;1
Zurück zum Zitat Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5(11):863–873PubMed Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR (2004) Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5(11):863–873PubMed
Zurück zum Zitat Zucca FA, Segura-Aguilar J, Ferrari E, Muñoz P, Paris I, Sulzer D, Sarna T, Casella L, Zecca L (2017) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Prog Neurobiol 155:96–119PubMed Zucca FA, Segura-Aguilar J, Ferrari E, Muñoz P, Paris I, Sulzer D, Sarna T, Casella L, Zecca L (2017) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson’s disease. Prog Neurobiol 155:96–119PubMed
Zurück zum Zitat Zucca FA, Vanna R, Cupaioli FA, Bellei C, De Palma A, Di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, Sulzer D, Zecca L (2018) Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson's disease. NPJ Parkinsons Dis 4:17PubMedPubMedCentral Zucca FA, Vanna R, Cupaioli FA, Bellei C, De Palma A, Di Silvestre D, Mauri P, Grassi S, Prinetti A, Casella L, Sulzer D, Zecca L (2018) Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson's disease. NPJ Parkinsons Dis 4:17PubMedPubMedCentral
Metadaten
Titel
The role of alpha-synuclein as ferrireductase in neurodegeneration associated with Parkinson’s disease
verfasst von
Jeswinder Sian-Hulsmann
Peter Riederer
Publikationsdatum
21.04.2020
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 5/2020
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-020-02192-0

Weitere Artikel der Ausgabe 5/2020

Journal of Neural Transmission 5/2020 Zur Ausgabe

Neurology and Preclinical Neurological Studies - Review Article

Non-pharmacological management of cognitive impairment in Parkinson’s disease

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.